Overall, these results suggest that, in the absence of spliceosome gene mutations, which is confirmed in this study, the observed expression changes are a consequence of the oncogenic mechanisms of CML and, particularly, of the aberrant TK activity of the BCR::ABL protein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.